Prestigious Late-Breaking Research Session Positions PH-762 as a Promising New PD-1 Directed Immunotherapy Candidate on March 28, 2026 at 3 PM (MDT)King of Prussia, Pennsylvania--(Newsfile Corp. - March 23, 2026) - Phio

<p>Prestigious Late-Breaking Research Session Positions PH-762 as a Promising New PD-1 Directed Immunotherapy Candidate on March 28, 2026 at 3 PM (MDT)</p><p>King of Prussia, Pennsylvania--(Newsfile Corp. - March 23, 2026) - Phio Pharmaceuticals Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/PHIO">PHIO</a>) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL<sup>&#174;</sup> gene silencing technology to eliminate cancer. Phio announced today that a podium presentation addressing its lead product candidate, PH-762, will be given in the American Academy of Dermatology's Late-Breaking Research Session S034 on March 28, 2026 in Denver, Colorado. </p><p>The presentation, entitled <i>"PD-1 Directed Intratumoral Immunotherapy: Results of an Escalating Dose Study of INTASYL PH-762 for Cutaneous Carcinomas</i><b>", </b>will highlight results of Phio's Phase 1b clinical study (NCT 06014086) which evaluated the safety and tolerability of neoadjuvant use of intratumoral PH-762 in cutaneous squamous cell carcinoma (cSCC), melanoma and Merkel cell carcinoma.</p><p>"The clinical study results are encouraging and firmly guide Phio to continued clinical development of this immuno-oncology therapy for cutaneous squamous cell carcinoma," said Mary Spellman M.D., Phio's acting Chief Medical Officer. "Preliminary clinical evidence demonstrates that intratumoral PH-762 may provide substantial clinical benefit, with notable pathologic response, and modest mean reductions in tumor burden following treatment."</p><table cellspacing="0" cellpadding="0" style="text-align: start; width: 100%; border-collapse: collapse;" border="0"><tbody><tr><td colspan="2" style="vertical-align: top;"><u><b>Presentation Details for S034 Late-Breaking Research Session 2</b></u></td></tr><tr><td style="vertical-align: top;"><b>Title:</b></td><td style="width: 80%; vertical-align: top;">PD-1 Directed Intratumoral Immunotherapy Results of an Escalating Dose Study of  INTASYL PH-762 for Cutaneous Carcinomas</td></tr><tr><td style="vertical-align: top;"><b>Presenter:</b></td><td style="width: 80%; vertical-align: top;">Mary Spellman, MD, FAAD</td></tr><tr><td style="vertical-align: top;"><b>Time:</b></td><td style="width: 80%; vertical-align: top;">3:00 - 3:12 PM (MDT)</td></tr><tr><td style="vertical-align: top;"><b>Date:</b></td><td style="width: 80%; vertical-align: top;">March 28, 2026</td></tr><tr><td style="vertical-align: top;"><b>Location: </b></td><td style="width: 80%; vertical-align: top;">Bellco Theatre, Colorado Convention Center, Denver, Colorado</td></tr></tbody></table><p>&#160;</p><p><b>Recent Company Highlights</b></p><p>Phio's lead clinical candidate, PH-762, is being evaluated as an intratumoral therapy for cutaneous squamous cell carcinoma (cSCC), melanoma and Merkel cell carcinoma. In its Phase 1b trial, Phio has reported that 22 patients completed treatment across five dose-escalation cohorts, with no dose-limiting toxicities or serious adverse events. The Company has also reported a pathological response rate in cSCC across all dosing cohorts of approximately 65%, including an 85% pathological response (6 of 7 patients) in the highest-dose cohort.</p><p>Phio has indicated that FDA engagement regarding next-stage clinical development is targeted for the second quarter of 2026 and has reported cash and cash equivalents projected to sustain operations into the first half of 2027.</p><p><b>About Phio Pharmaceuticals Corp.</b> </p><p>Phio Pharmaceuticals Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/PHIO">PHIO</a>) is a clinical-stage siRNA biopharmaceutical company advancing its INTASYL<sup>&#174;</sup> gene silencing technology in immuno-oncology. Phio's INTASYL compounds are designed to enhance the body's immune cells to more effectively kill cancer cells. Notably, INTASYL is a self-delivering RNAi technology focused on immuno-oncology therapeutics without the need for formulation enhancements or manipulations to reach its target. Phio's lead clinical program is an INTASYL compound, PH-762, that silences the PD-1 gene implicated in various forms of skin cancer. The Phase 1b trial (NCT# 06014086) evaluated PH-762 for the treatment of cutaneous squamous cell carcinoma, melanoma and Merkel cell carcinoma. PH-762 is a potential non-surgical treatment for skin cancers.</p><p>For additional information, visit the Company's website, <a href="https://api.newsfilecorp.com/redirect/7nDKnCMWEY">www.phiopharma.com</a>.  </p><p><b>Forward Looking Statements</b> </p><p><i>This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as "intends," "believes," "anticipates," "indicates," "plans," "expects," "suggests," "may," "would," "should," "potential," "designed to," "will," "ongoing," "estimate," "forecast," "target," "predict," "could" and similar references, although not all forward-looking statements contain these words. These statements, which include statements regarding the anticipated benefits of our INTASYL&#8482; RNAi platform, the results from our ongoing clinical trials, our expectations that our cash runway will extend into the first half of 2027, our expectations regarding timing of FDA submissions intended to propose and seek guidance for next steps in clinical study design for PH-762, details regarding our planned non-clinical toxicology study, and our ability to support ongoing clinical development, operational requirements and strategic initiatives with the capital we currently have on hand, are based only on our current beliefs, expectations and assumptions and are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results may differ materially from those indicated in the forward-looking statements as a result of a number of important factors, including, but not limited to, the impact to our business and operations by inflationary pressures, rising interest rates, recession fears, the development of our product candidates, results from our preclinical and clinical activities, our ability to execute on business strategies, our ability to develop our product candidates with collaboration partners, and the success of any such collaborations, the timeline and duration for advancing our product candidates into clinical development, the timing or likelihood of regulatory filings and approvals, the success of our efforts to commercialize our product candidates if approved, our ability to manufacture and supply our product candidates for clinical activities, and for commercial use if approved, the scope of protection we are able to establish and maintain for intellectual property rights covering our technology platform, our ability to obtain future financing, market and other conditions and those risks identified in our Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q under the caption "Risk Factors" and in other filings the Company periodically makes with the SEC. Readers are urged to review these risk factors and to not act in reliance on any forward-looking statements, as actual results may differ from those contemplated by our forward-looking statements. Phio does not undertake to update forward-looking statements to reflect a change in its views, events or circumstances that occur after the date of this release, except as required by law.</i></p><p>For additional information, visit the Company's website, <a href="https://api.newsfilecorp.com/redirect/ej2njcMB0K">www.phiopharma.com</a>.</p><div id="contactInfo"><p><b>Contact:<br />Phio Pharmaceuticals Corp.<br /></b>Jennifer Phillips: <a href="mailto:jphillips@phiopharma.com">jphillips@phiopharma.com</a>&#160;<br />Corporate Affairs</p></div><p id="corporateNewsLogoContainer"><img src="https://images.newsfilecorp.com/files/10407/289479_522748bf0497eaa6_logo.jpg" id="corporateNewsLogo" alt="Corporate Logo" /></p><p id="corporateLinkBack">To view the source version of this press release, please visit <a href="https://api.newsfilecorp.com/redirect/87rK7uO7Ep">https://www.newsfilecorp.com/release/289479</a></p><p><img src="https://api.newsfilecorp.com/newsinfo/289479/197" alt="" /></p>

PHIO

Phio Pharmaceuticals Announces American Academy of Dermatology 2026 Presentation Featuring Clinical Study Results from Study of PH-762 for Cutaneous Carcinoma Underscoring Clinical Pipeline Advancement

PH-762 Presentation Highlights Strong Phase 1b Results in Skin Cancer Therapy

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>Prestigious Late-Breaking Research Session Positions PH-762 as a Promising New PD-1 Directed Immunotherapy Candidate on March 28, 2026 at 3 PM (MDT)King of Prussia, Pennsylvania--(Newsfile Corp. - March 23, 2026) - Phio</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Phio Pharmaceuticals&#039; lead candidate, PH-762, shows a promising 65% pathological response in a Phase 1b trial for skin cancer, with major presentation scheduled for March 28, 2026. This development could enhance investor confidence ahead of anticipated FDA discussions in Q2 2026, potentially impacting stock valuation positively.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>Phio&#039;s PH-762 to be presented at a major dermatology conference.</li><li>The presentation covers Phase 1b trial results for skin cancer therapy.</li><li>Results show 65% pathological response rate across trial cohort.</li><li>FDA engagement for clinical development is targeted by mid-2026.</li><li>Phio&#039;s cash reserves projected to last through first half of 2027.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>Phio Pharmaceuticals Corp. (PHIO)</strong>: The company is focusing on advancing its immunotherapy candidate PH-762.</li></ul>
  </section>

  <section data-block="category">
    <h3>Corporate Developments</h3>
    <p>This press release falls under &#039;Corporate Developments&#039; as it highlights pivotal clinical trial results and upcoming presentations that directly influence investor perspectives and strategic decisions regarding PHIO.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>Investors should watch for sentiment around PH-762 data release on March 28.</li><li>Future FDA feedback could significantly affect PHIO&#039;s valuation and stock price.</li><li>The strong pathological response rate could lead to increased institutional interest.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>The Phase 1b trial involved 22 patients with zero dose-limiting toxicities.</li><li>85% pathological response in the highest-dose cohort in Phase 1b.</li><li>FDA engagement for further clinical development targeted for Q2 2026.</li><li>Presentation scheduled at 3 PM MDT on March 28, 2026.</li><li>Cash reserves will sustain operations into the first half of 2027.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Buy PHIO shares ahead of the March 28 conference considering positive trial results.</p>
  </section>
</section>


<p>Prestigious Late-Breaking Research Session Positions PH-762 as a Promising New PD-1 Directed Immunotherapy Candidate on March 28, 2026 at 3 PM (MDT)</p><p>King of Prussia, Pennsylvania--(Newsfile Corp. - March 23, 2026) - Phio Pharmaceuticals Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/PHIO">PHIO</a>) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL<sup>&#174;</sup> gene silencing technology to eliminate cancer. Phio announced today that a podium presentation addressing its lead product candidate, PH-762, will be given in the American Academy of Dermatology's Late-Breaking Research Session S034 on March 28, 2026 in Denver, Colorado. </p><p>The presentation, entitled <i>"PD-1 Directed Intratumoral Immunotherapy: Results of an Escalating Dose Study of INTASYL PH-762 for Cutaneous Carcinomas</i><b>", </b>will highlight results of Phio's Phase 1b clinical study (NCT 06014086) which evaluated the safety and tolerability of neoadjuvant use of intratumoral PH-762 in cutaneous squamous cell carcinoma (cSCC), melanoma and Merkel cell carcinoma.</p><p>"The clinical study results are encouraging and firmly guide Phio to continued clinical development of this immuno-oncology therapy for cutaneous squamous cell carcinoma," said Mary Spellman M.D., Phio's acting Chief Medical Officer. "Preliminary clinical evidence demonstrates that intratumoral PH-762 may provide substantial clinical benefit, with notable pathologic response, and modest mean reductions in tumor burden following treatment."</p><table cellspacing="0" cellpadding="0" style="text-align: start; width: 100%; border-collapse: collapse;" border="0"><tbody><tr><td colspan="2" style="vertical-align: top;"><u><b>Presentation Details for S034 Late-Breaking Research Session 2</b></u></td></tr><tr><td style="vertical-align: top;"><b>Title:</b></td><td style="width: 80%; vertical-align: top;">PD-1 Directed Intratumoral Immunotherapy Results of an Escalating Dose Study of  INTASYL PH-762 for Cutaneous Carcinomas</td></tr><tr><td style="vertical-align: top;"><b>Presenter:</b></td><td style="width: 80%; vertical-align: top;">Mary Spellman, MD, FAAD</td></tr><tr><td style="vertical-align: top;"><b>Time:</b></td><td style="width: 80%; vertical-align: top;">3:00 - 3:12 PM (MDT)</td></tr><tr><td style="vertical-align: top;"><b>Date:</b></td><td style="width: 80%; vertical-align: top;">March 28, 2026</td></tr><tr><td style="vertical-align: top;"><b>Location: </b></td><td style="width: 80%; vertical-align: top;">Bellco Theatre, Colorado Convention Center, Denver, Colorado</td></tr></tbody></table><p>&#160;</p><p><b>Recent Company Highlights</b></p><p>Phio's lead clinical candidate, PH-762, is being evaluated as an intratumoral therapy for cutaneous squamous cell carcinoma (cSCC), melanoma and Merkel cell carcinoma. In its Phase 1b trial, Phio has reported that 22 patients completed treatment across five dose-escalation cohorts, with no dose-limiting toxicities or serious adverse events. The Company has also reported a pathological response rate in cSCC across all dosing cohorts of approximately 65%, including an 85% pathological response (6 of 7 patients) in the highest-dose cohort.</p><p>Phio has indicated that FDA engagement regarding next-stage clinical development is targeted for the second quarter of 2026 and has reported cash and cash equivalents projected to sustain operations into the first half of 2027.</p><p><b>About Phio Pharmaceuticals Corp.</b> </p><p>Phio Pharmaceuticals Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/PHIO">PHIO</a>) is a clinical-stage siRNA biopharmaceutical company advancing its INTASYL<sup>&#174;</sup> gene silencing technology in immuno-oncology. Phio's INTASYL compounds are designed to enhance the body's immune cells to more effectively kill cancer cells. Notably, INTASYL is a self-delivering RNAi technology focused on immuno-oncology therapeutics without the need for formulation enhancements or manipulations to reach its target. Phio's lead clinical program is an INTASYL compound, PH-762, that silences the PD-1 gene implicated in various forms of skin cancer. The Phase 1b trial (NCT# 06014086) evaluated PH-762 for the treatment of cutaneous squamous cell carcinoma, melanoma and Merkel cell carcinoma. PH-762 is a potential non-surgical treatment for skin cancers.</p><p>For additional information, visit the Company's website, <a href="https://api.newsfilecorp.com/redirect/7nDKnCMWEY">www.phiopharma.com</a>.  </p><p><b>Forward Looking Statements</b> </p><p><i>This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as "intends," "believes," "anticipates," "indicates," "plans," "expects," "suggests," "may," "would," "should," "potential," "designed to," "will," "ongoing," "estimate," "forecast," "target," "predict," "could" and similar references, although not all forward-looking statements contain these words. These statements, which include statements regarding the anticipated benefits of our INTASYL&#8482; RNAi platform, the results from our ongoing clinical trials, our expectations that our cash runway will extend into the first half of 2027, our expectations regarding timing of FDA submissions intended to propose and seek guidance for next steps in clinical study design for PH-762, details regarding our planned non-clinical toxicology study, and our ability to support ongoing clinical development, operational requirements and strategic initiatives with the capital we currently have on hand, are based only on our current beliefs, expectations and assumptions and are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results may differ materially from those indicated in the forward-looking statements as a result of a number of important factors, including, but not limited to, the impact to our business and operations by inflationary pressures, rising interest rates, recession fears, the development of our product candidates, results from our preclinical and clinical activities, our ability to execute on business strategies, our ability to develop our product candidates with collaboration partners, and the success of any such collaborations, the timeline and duration for advancing our product candidates into clinical development, the timing or likelihood of regulatory filings and approvals, the success of our efforts to commercialize our product candidates if approved, our ability to manufacture and supply our product candidates for clinical activities, and for commercial use if approved, the scope of protection we are able to establish and maintain for intellectual property rights covering our technology platform, our ability to obtain future financing, market and other conditions and those risks identified in our Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q under the caption "Risk Factors" and in other filings the Company periodically makes with the SEC. Readers are urged to review these risk factors and to not act in reliance on any forward-looking statements, as actual results may differ from those contemplated by our forward-looking statements. Phio does not undertake to update forward-looking statements to reflect a change in its views, events or circumstances that occur after the date of this release, except as required by law.</i></p><p>For additional information, visit the Company's website, <a href="https://api.newsfilecorp.com/redirect/ej2njcMB0K">www.phiopharma.com</a>.</p><div id="contactInfo"><p><b>Contact:<br />Phio Pharmaceuticals Corp.<br /></b>Jennifer Phillips: <a href="mailto:jphillips@phiopharma.com">jphillips@phiopharma.com</a>&#160;<br />Corporate Affairs</p></div><p id="corporateNewsLogoContainer"><img src="https://images.newsfilecorp.com/files/10407/289479_522748bf0497eaa6_logo.jpg" id="corporateNewsLogo" alt="Corporate Logo" /></p><p id="corporateLinkBack">To view the source version of this press release, please visit <a href="https://api.newsfilecorp.com/redirect/87rK7uO7Ep">https://www.newsfilecorp.com/release/289479</a></p><p><img src="https://api.newsfilecorp.com/newsinfo/289479/197" alt="" /></p>

Phio Pharmaceuticals' lead candidate, PH-762, shows a promising 65% pathological response in a Phase 1b trial for skin cancer, with major presentation scheduled for March 28, 2026. This development could enhance investor confidence ahead of anticipated FDA discussions in Q2 2026, potentially impacting stock valuation positively.

phio-pharmaceuticals-announces-american-academy-of-dermatology-2026-presentation-featuring-clinical-study-results-from-study-of-ph-762-for-cutaneous-carcinoma-underscoring-clinical-pipeline-advancement

Phio Pharmaceuticals Announces American Academy of Dermatology 2026 Presentation Featuring Clinical Study Results from Study of PH-762 for Cutaneous Carcinoma Underscoring Clinical Pipeline Advancement

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Corporate Developments

Related News